# US 2026/0229312 A1 · HLA Tissue Matching And Methods Therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0229312 A1
- Document ID: US20260229312A1
- Status: Published application
- Kind: A1
- Application number: 19/635,120
- Filed: 2026-03-31
- Published: 2026-08-06
- Earliest claimed: 2017-09-06
- Assignees: Nant Holdings IP, LLC; NantOmics, LLC
- Applicants: Nant Holdings IP, LLC
- Inventors: Patrick Soon-Shiong; John Zachary Sanborn
- Web page: https://patentgrep.com/patent/US20260229312A1

## CPC

- G16B 35/10: Design of libraries
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 30/10: Sequence alignment; Homology search
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B 50/30: Data warehousing; Computing architectures
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Contemplated systems and methods use high-accuracy in silico HLA analysis to so establish a transplant match database suitable for transplantation, and particularly stem cell and solid organ transplant.

## Claims

### Claim 1

A bank for storage of biological material, comprising:
a processing facility for the biological material;
a sequencing facility operationally coupled to the processing facility and configured to produce omics data from the biological material, wherein the omics data comprise a plurality of sequence reads;
a computer-based HLA analysis engine operationally coupled to the sequencing facility and comprising at least one processor and at least one computer readable memory storing software instructions, wherein the at least one processor performs the following operations upon execution of the software instructions:
(i) decomposing the plurality of sequence reads into a plurality of respective sets of k-mers;
(ii) generating a composite de Bruijn graph using the plurality of respective sets of k-mers, and a reference sequence that includes a plurality of sequences of known and distinct HLA alleles;
(iii) ranking each of the known and distinct HLA alleles using a composite match score that is calculated from respective votes of the plurality of sequence reads, and wherein each vote uses k-mers that match corresponding segments in the known and distinct HLA alleles;
(iv) identifying a top ranked HLA allele as the first HLA-type of the biological material; and
(v) re-ranking remaining non-top-ranking known and distinct HLA alleles using an adjusted composite match score to identify an adjusted top-ranking HLA allele as the second HLA-type of the biological material;
an HLA database informationally coupled to the computer-based HLA analysis engine and configured to store the first HLA-type and the second HLA-type for the biological material; and
a storage facility configured to bank the to biological material.

### Claim 2 (depends on 1)

The bank of claim 1, further comprising a matching engine configured to match the first and/or second HLA types with a donor or recipient HLA-type.

### Claim 3 (depends on 2)

The bank of claim 2, wherein the matching engine is configured to operate as a donor registry and/or as a recipient registry.

### Claim 4 (depends on 2)

The bank of claim 2, wherein the matching engine is configured to receive an HLA matching request from a remote location.

### Claim 5 (depends on 4)

The bank of claim 4, wherein the remote location is selected from the group consisting of a clinic, a physician's office, a clinical laboratory, an oncology group, and a commercial sequencing entity.

### Claim 6 (depends on 1)

The bank of claim 1, wherein the bank is configured to perform omics analysis on banked tissue.

### Claim 7 (depends on 1)

The bank of claim 1, wherein the bank is configured to perform omics analysis on fresh tissue.

### Claim 8 (depends on 1)

The bank of claim 1, wherein the biological material is selected from the group consisting of whole blood, cord blood, stem cells, bone marrow aspirate, a donor organ, cultured cells, and cultured tissue.

### Claim 9 (depends on 1)

The bank of claim 1, wherein the first and/or the second HLA type is determined to a depth of at least four digits.

### Claim 10 (depends on 1)

The bank of claim 1, wherein the first and/or the second HLA type is determined to a depth of at least six digits.

### Claim 11 (depends on 1)

The bank of claim 1, wherein the first and/or the second HLA type include one or more of the following: an HLA-A type, an HLA-B type, an HLA-C type, and HLA-DRB-1 type, and an HLA-DQB-1 type.

### Claim 12 (depends on 1)

The bank of claim 1, wherein the omics data comprise partial omics data, and wherein the partial omics data comprises data from one chromosome.

### Claim 13 (depends on 12)

The bank of claim 12, wherein the data from one chromosome represent chromosome 6p21.3.

### Claim 14 (depends on 12)

The bank of claim 12, wherein the omics data is derived from at least one of the following: RNAseq data, whole genome sequencing, exome sequencing, transcriptome sequencing, and targeted sequencing.

### Claim 15 (depends on 1)

The bank of claim 1, wherein the known HLA alleles represent at least 26 HLA types.

### Claim 16 (depends on 1)

The bank of claim 1, wherein the k-mers have length less then 50.

### Claim 17 (depends on 16)

The bank of claim 16, wherein the k-mers have a length between 10 and 30.

### Claim 18 (depends on 1)

The bank of claim 1, wherein the adjusted composite match score is adjusted using depth of coverage.

### Claim 19 (depends on 1)

The bank of claim 1, wherein the omics data are further ordered or generated to determine ancestry, ethnicity, or health status.

### Claim 20 (depends on 1)

The bank of claim 1, wherein the omics data are associated with a personalized treatment for cancer.
